R&D Trends

CFFT, Pfizer expand collaboration on cystic fibrosis by $58M

Monday, November 19, 2012 02:46 PM

Cystic Fibrosis Foundation Therapeutics (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, has expanded its research collaboration with Pfizer designed to discover new drugs to treat people with the most common mutation of cystic fibrosis (CF), Delta F508.

More... »

Chiromics, GSK enter into collaboration

Monday, November 19, 2012 12:09 PM

Chiromics, a drug discovery company, has formed a collaboration with global healthcare company GlaxoSmithKline to discover novel classes of small molecules against certain biological targets.

More... »

Factor Bioscience awarded two NIH grants for Alzheimer's research

Monday, November 19, 2012 11:12 AM

The National Institutes of Health, through the National Center for Advancing Translational Sciences, has awarded Factor Bioscience, a developer of cell-based therapeutics and research tools, two Small Business Innovation Research (SBIR) grants to accelerate the development of new treatments for Alzheimer's disease.

More... »

Sanofi, T1D Exchange to investigate optimal care for young people with diabetes

Friday, November 16, 2012 02:06 PM

Sanofi, a global healthcare comapny, and T1D Exchange, a non-profit organization focused on type 1 diabetes, will collaborate on the TEENs registry study, which aims to provide the type 1 diabetes community with a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes, and to deliver recommendations for better disease management and patients outcomes.

More... »

New report shows more than 220 drugs in pipeline for diabetes

Thursday, November 15, 2012 08:00 AM

America's biopharmaceutical research companies currently are developing 221 innovative new medicines to help the nearly 26 million patients in the U.S. affected by diabetes.

More... »

Forest Labs, Adamas to develop fixed dose combo of Namenda XR and Donepezil for Alzheimer's

Wednesday, November 14, 2012 02:45 PM

Forest Laboratories, an international pharmaceutical company, and Adamas Pharmaceuticals, an Emeryville, Calif.-based therapeutics company focused on CNS disorders, have entered into an agreement for the development and commercialization of a fixed dosed combination (FDC) of Namenda XR (memantine HCl extended release) and donepezil HCl as a once daily therapy for the treatment of moderate to severe dementia of the Alzheimer's type in the U.S.

More... »

GNS Healthcare, Dana-Farber, Mount Sinai to build computer model of multiple myeloma

Tuesday, November 13, 2012 01:57 PM

GNS Healthcare, a healthcare data analytics company, has entered into a collaboration with Dana-Farber Cancer Institute and the Mount Sinai School of Medicine to create a data-driven computer model of multiple myeloma, the second most common blood cancer in the U.S.

More... »

Foundation Medicine, AZ collaborate on genomic profiling for targeted cancer therapies

Tuesday, November 13, 2012 09:23 AM

Foundation Medicine, a molecular information company based in Cambridge, Mass., has formed a multi-year collaboration with global biopharmaceutical company AstraZeneca to identify alterations found in cancer-related tumor genes that may predict a person's response or resistance to targeted medicines.

More... »

Northwest Bio collaborates with U.K. cancer institutions for DCVaxR-Direct trial

Wednesday, November 7, 2012 11:51 AM

Northwest Biotherapeutics, a Bethesda, Md.-based biotechnology company developing DCVax personalized immune therapies for cancer, has initiated a collaboration with U.K.-based cancer institutions Sarah Cannon Research U.K. and Leaders in Oncology Care (LOC) on a phase I/II trial with DCVax-Direct for metastatic colon cancer. 

More... »

U.K. government awards $2.7M grant to PsiOxus cancer vaccine

Wednesday, November 7, 2012 10:57 AM

PsiOxus Therapeutics, a development stage biotechnology company based in the U.K was awarded a $2.7 million grant from the U.K. government-backed Biomedical Catalyst to initiate a phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

More... »